key: cord-0703958-fp2awg9y
authors: Robertson, Elaine; Reeve, Kelly S.; Niedzwiedz, Claire L.; Moore, Jamie; Blake, Margaret; Green, Michael; Vittal Katikireddi, Srinivasa; Benzeval, Michaela J.
title: Predictors of COVID-19 vaccine hesitancy in the UK Household Longitudinal Study
date: 2021-03-11
journal: Brain Behav Immun
DOI: 10.1016/j.bbi.2021.03.008
sha: 9427b5f8d57ae93e1773e8d666b1a8a3907ed5ac
doc_id: 703958
cord_uid: fp2awg9y

Vaccine hesitancy could undermine efforts to control COVID-19. We investigated the prevalence of COVID-19 vaccine hesitancy in the UK and identified vaccine hesitant subgroups. The ‘Understanding Society’ COVID-19 survey asked participants (n=12,035) their likelihood of vaccine uptake and reason for hesitancy. Cross-sectional analysis assessed vaccine hesitancy prevalence and logistic regression calculated odds ratios. Overall vaccine hesitancy was low (18% unlikely/very unlikely). Vaccine hesitancy was higher in women (21.0% vs 14.7%), younger age groups (26.5% in 16-24 year olds vs 4.5% in 75+) and those with lower education levels (18.6% no qualifications vs 13.2% degree qualified). Vaccine hesitancy was high in Black (71.8%) and Pakistani/Bangladeshi (42.3%) ethnic groups. Odds ratios for vaccine hesitancy were 13.42 (95% CI:6.86, 26.24) in Black and 2.54 (95% CI:1.19, 5.44) in Pakistani/Bangladeshi groups (compared to White British/Irish) and 3.54 (95%CI:2.06, 6.09) for people with no qualifications versus degree. Urgent action to address hesitancy is needed for some but not all ethnic minority groups.

Vaccines and immunisation programmes save lives. The World Health Organisation (WHO) estimates that immunisation programmes across the world prevent 2-3 million deaths every year and are not only cost effective but a key element of preventative healthcare. 1 Since the emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in 2019, the global pandemic has resulted in over 72 million confirmed cases and 1.6 million deaths in 220 countries worldwide (as at 18 Dec 2020). 2 An effective and safe vaccine is vital to controlling the COVID-19 outbreak. However, not only does a vaccine need to be safe and effective, it must also be taken up by those people at greatest risk of harm from the disease. Ideally, uptake by a large enough proportion of the population will offer protection to people who remain unimmunised, referred to as achieving 'herd immunity'. For COVID-19, vaccine uptake would need to be between approximately 67% and 80% to reduce spread of the disease. 3, 4 Understanding who will take up a vaccine, who plans not to or are uncertain, and why, is critical to designing a successful vaccination programme.

Even before the emergence of SARS-CoV-2, WHO had already highlighted vaccine hesitancy as one of the ten leading threats to global health. 5 The WHO Strategic Advisory Group of Experts Working Group on Vaccine Hesitancy define it as the "delay in acceptance or refusal of safe vaccines despite availability of vaccination services". 6 Reasons for vaccine hesitancy are acknowledged as being complex but also context specific. Hesitancy around uptake can vary geographically, at different times and for different vaccines by a range of factors including complacency around the disease, convenience of access and confidence in the vaccine itself. For example, in the H1N1 pandemic of 2009, there was a perception that the vaccine was rushed and unsafe. 7 Similar concerns have been raised about the speed of COVID-19 vaccine development. 4 Studies into potential COVID-19 vaccination, based on non-representative samples, have indicated that vaccine hesitancy associated with age, gender, income, education level and ethnicity will be an issue. [8] [9] [10] [11] In studies conducted prior to vaccine approval, hesitancy rates for a COVID-19 vaccine in the general UK population varied greatly, from approximately 12% 12 to 31%. 9 In studies where ethnicity was considered, small sample sizes did not allow for detailed analysis of specific ethnic groups, but suggested greater hesitancy amongst people classified as non-White. [9] [10] [11] [12] This is particularly important, given the often greater risk of COVID-19 harms observed among several ethnic minority groups. [13] [14] [15] The COVID-19 pandemic has been described as a 'syndemic' where it not only acts together with, but worsens and amplifies, non-communicable diseases and social conditions and hence exacerbates inequalities in health. 16 As inequalities already exist in seasonal influenza and pneumococcal vaccine uptake, with lower uptake in more deprived areas 17, 18 , there is reason to believe that inequalities will exist in vaccine uptake against COVID-19. Understanding if some subgroups of the population are more likely to be vaccine hesitant will help in the formulation of vaccination programme strategies to ensure adequate population coverage to achieve herd immunity and minimise health inequalities. This will be particularly important if greater vaccine hesitancy is found among groups at greater risk from COVID-19. We therefore aimed to describe how willing the UK population is to be vaccinated against COVID-19, to identify which population subgroups are more likely to be vaccine hesitant, which are more likely to take up a vaccine, and describe the main reasons given for both vaccine uptake and vaccine hesitancy.

The UK Household Longitudinal Study, also referred to as 'Understanding Society', is a nationally representative panel study, based on a clustered-stratified probability sample of UK households, with boost samples of key ethnic minority groups. Sample members living in the UK have been interviewed annually since 2009. 19 In 2020, during the COVID-19 pandemic, participants aged 16+ years who had lived in households that had completed at least one of the last two waves of the main Understanding Society survey were invited to take part in the COVID-19 survey either online or by telephone (n=42,330). Web surveys took place monthly from April to July, then every two months. 20 For wave 6, carried out from 24 th November to 1 st December 2020, only sample members who had completed at least one partial interview in any of the preceding five COVID-19 web surveys, and had not become ineligible through death or moving abroad nor opted out of the study, were invited to take part. This resulted in 19,289 invitations being issued, and 12,035 took part, a response rate of 62%. 21 Data for age, sex, ethnicity, education level and country of birth were derived from previous waves of the main study. 22 Ethics approval was granted by the University of Essex Ethics Committee for the COVID-19 surveys (ETH1920-1271). No additional ethical approval was necessary for this secondary data analysis.

Our primary outcome was vaccine hesitancy, assessed by asking all participants "Imagine that a vaccine against COVID-19 was available for anyone who wanted it. How likely or unlikely would you be to take the vaccine?" Possible responses were "Very likely", "Likely", "Unlikely" and "Very unlikely". This was collapsed into a binary variable for modelling comparing 'unlikely and very unlikely', classified as vaccine hesitant, to 'likely or very likely'. If a participant tried to bypass the question, they were given the option of 'don't know'(n=45) and, given the size of the group they were coded as missing.

Secondary outcomes included reasons for vaccine hesitancy. Vaccine hesitant participants were asked "What is the main reason you would not take the vaccine?" and asked to pick one main reason from a list of 12 possible answers ( Figure 3 ). Participants who were not vaccine hesitant were asked "What would be your main reason for taking the vaccine?" and asked to choose one main reason from a list of 11 possible answers ( Figure 3 ). All participants were then asked "Which three of these things would most increase the chances of you choosing to get vaccinated?" and given a list of 9 possible answers ( Figure 3 ). For the purpose of this analysis, we identified if the item was mentioned as any of the three options.

Covariates are all taken from the longitudinal mainstage data files. Statistical models included age, coded in 5-year age bands to allow for non-linearity in the relationship, and gender coded as male/female. Ethnicity was self-reported and coded as White 

Descriptive statistics (percentages and 95% confidence intervals (CI)) for the outcomes were calculated using cross-sectional weights to make the sample representative of the UK community dwelling population. Weights were calculated for each COVID-web survey based on differential non-response from wave 9. Predictors included in the weights were basic demographic factors, household composition, previous survey outcomes, survey paradata, such as the number of reminders issued, economic and health variables. The final weights are calculated as the inverse of the response propensity. 20

Weights are not calculated for the 1,974 participants who did not take part at Wave 9, and hence they are excluded from the weighted analyses, hence the weighted sample is 9,981.

Logistic regression was used because the dependent variable was binary. Three models were considered: model 0 -univariate models for each covariate, model 1 -statistical analysis including age and gender, model 2 -statistical analysis including all covariates.

Data were cleaned using SPSS version 25 and analysed in R version 3.6.3 23 using the complex samples method to take account of the clustered and stratified sample 24 .

Missing data were excluded from the analyses using listwise deletion so each model may contain different numbers of participants.

Understanding Society data are available through the UK Data Service. COVID-19 Survey is available here https://beta.ukdataservice.ac.uk/datacatalogue/studies/study?id=8644, and the mainstage here https://beta.ukdataservice.ac.uk/datacatalogue/studies/study?id=6614.

Researchers who would like to use Understanding Society need to register with the UK Data Service before being allowed to apply for or download datasets.

This project has employed statistical analytical techniques standard in all statistical packages.

12,035 participants completed the Covid-19 wave 6 survey online and the weighted sample is 9,981 ( Figure 1 ). However, in the weighted sample 56 participants did not answer the vaccine hesitancy question and 591 participants had missing data on at least one covariate, and hence the weighted analytical sample for the full multivariable models is 9,390, although in other models it varies based on the covariates included.

The weighted study sample is described in Table 1 .

Overall, intention to have the COVID-19 vaccine was high, 53.5% of participants were very likely and a further 28.5% were likely to be vaccinated with 18% being vaccine hesitant (reporting unlikely or very unlikely). However, there was marked variation in population subgroups (Figure 2 being likely/very likely to take a vaccine) and the any other Asian background group (86.1%; this group includes participants of Chinese ethnicity). Vaccine hesitancy varied with education level. Vaccine hesitancy was lowest in those with degrees (13.2%) and highest in those with GCSE level education (24.6%).

The main reasons for vaccine hesitancy were concerns over future unknown effects of a vaccine, with 42.7% citing this as their main reason ( Figure 3 ). The main reasons for being willing to take up a vaccine were to avoid catching COVID-19 or becoming ill from the disease (54.6%) and to allow social and family life to get back to normal (12.5%).

Stated reasons for vaccine hesitancy were often similar across ethnic groups (Appendix 1). However, when compared to the White British/Irish group, Black/Black British participants were more likely to state they 'Don't trust vaccines' (29.2% vs 5.7%) and the Pakistani/Bangladeshi ethnic group cited worries about side-effects (35.4% vs 8.6%) more commonly. Women were more likely than men to state that their main reason for vaccine hesitancy was concern about side effects and to state that they do not trust vaccines.

A majority of participants (67.8%) reported that knowing a vaccine reduced their risk of catching COVID-19 was a factor that would increase their chance of taking a vaccine 

The vast majority (82%) of UK adults are willing to take up a COVID-19 vaccine if offered with 18% being vaccine hesitant however marked differences exist across population subgroups. Older age and being male are strongest drivers of the risk of COVID-19 death, they are less likely to be vaccine hesitant, suggesting the vaccination programme could yield large health benefits within the UK. Very large differences in vaccine hesitancy exist by ethnicity, with Black/Black British and Pakistani/Bangladeshi ethnic groups being most hesitant. However, not all minority ethnic groups had higher vaccine hesitancy, highlighting the importance of understanding heterogeneity between minority ethnic groups. Overall, the main reasons given for vaccine hesitancy were fears around side effects and future adverse effects of a COVID-19 vaccine. The main reasons for intended vaccine uptake relate to the avoidance of catching the virus or becoming very ill from it, but also to allow social and family life to return to normal. Vaccine efficacy and safety were identified as factors that would encourage vaccine uptake.

Our study has several strengths. To our knowledge, it is the first large representative study in the UK to survey participants on likely vaccine uptake or hesitancy and the reasons why a COVID-19 vaccine would be accepted or refused. It also did so at a time when new vaccine development and vaccine efficacy was highly reported in the media (end November 2020, but just before the first vaccine was approved on 2 nd December 2020). The four countries of the UK are now rolling out a vaccination programme commencing with those most at risk of mortality from COVID-19. The findings reported here, provide evidence on the groups who need targeting and arguments that may be most persuasive for them.

There are also weaknesses of our study which should be noted. The survey is web-based so non-participation may have introduced bias into the results. However, and following recommended practice for this dataset, the results were weighted to account for nonresponse and attrition. 25 Furthermore, our main pattern of findings of which ethnic, age and gender groups were most likely to be vaccine hesitant was also seen in unweighted analyses (results not shown). Secondly, small numbers did not allow for detailed analysis of some ethnic groups. Additionally, we did not ask about the different types of vaccinations being developed and whether this would have any bearing on vaccine hesitancy. While we highlight associations between vaccine hesitancy and range of sociodemographic factors, the purpose of this analysis was descriptive. Willingness to be vaccinated is influenced by public health and other communications, as well as a broader range of social factors. These associations should therefore not be interpreted as immutable effects but rather guide vaccination planning.

There have been some other smaller UK studies of COVID-19 vaccine hesitancy which have not been based on representative samples. These studies indicated that 14% of participants were unwilling to receive a COVID-19 vaccine with a further 22% being unsure as to whether they would take this, with only 64% willing to take a COVID-19 vaccine. 10 A study conducted in Ireland and UK during the early phase of the pandemic found vaccine hesitancy of 35% and 31% in these populations respectively. 9 A nonprobability online survey in Autumn 2020 found 71.7% were willing to be vaccinated, 16 .6% were very unsure, and 11.7% were very vaccine hesitant. 12 A Scottish survey found uptake figures to be slightly higher at between 74-78%. A poll by Ipsos MORI in late October 2020 found 67% of the UK public said they were very (42%) or fairly (25%) likely to take a COVID-19 vaccine. 8 Our study suggests slightly higher vaccine uptake in the general UK population of 82% with vaccine hesitancy at 18%.

Given the age related focus of the Phase One vaccination roll out in the UK 26 , our study suggests that uptake is likely to be high in the target groups. However, the finding of greater vaccine hesitancy amongst some, but not all, ethnic minority groups is concerning and aligns with emerging evidence from other countries. This is not inevitable -studies focused on intention to receive vaccines prior to this pandemic have not consistently found greater levels of vaccine hesitancy among ethnic minority groups. 27, 28 Nevertheless, it needs to be a key focus of the design of vaccination programmes, given the higher prevalence of COVID-19 among ethnic groups and the need to avoid exacerbating existing inequalities. 29 Our study also found that those who had lower education levels were more likely to be vaccine hesitant suggesting that there similarly needs to be added focus on increasing vaccine uptake with those experiencing socioeconomic disadvantage who are at more risk of COVID-19. 14 Vaccine hesitancy rates vary by country and population subgroup. However, international evidence across several studies suggests that approximately 25% of the general population are hesitant about accepting a COVID-19 vaccine. [30] [31] [32] [33] [34] [35] A systematic review of studies on willingness to be vaccinated suggests 60% of people intend to be vaccinated, indicating the UK may be better placed to utilise vaccination to address the pandemic. 36 In some countries, such as Italy, previous vaccination rates suggest uptake may be too low to stop the spread of COVID-19. 37 Our study suggests that this is not the case in the UK and if everyone who has said they are likely or very likely to take up the vaccination if offered, actually get vaccinated, coverage in the UK could be high enough to achieve herd immunity. Existing research for vaccine hesitancy suggests that key drivers for uptake were perceived efficacy of a vaccine, concern over negative adverse effects and safety of a vaccine. 10, 33, 38 Our study also found fears over adverse effects and safety to be key reasons for vaccine hesitancy, especially future negative effects.

However, our study also adds that knowing that a vaccine is effective in reducing the spread of COVID-19 could increase uptake.

Our study has important practical implications for public health policy. There are identifiable subgroups of the UK population who are more likely to be vaccine hesitant.

Vaccine hesitancy is a complex problem 39 and as such a range of practical steps need to be undertaken to increase uptake. Firstly, the subgroups we have identified as being vaccine hesitant should be included in the planning and development of any engagement programmes. There is the potential to widen health inequalities without deliberate efforts to engage those groups who are most likely to be affected by COVID-19 and least likely to take up a vaccine. Initiatives to improve uptake in Black ethnic groups within the UK should be an urgent priority -for example, by working in close partnership with communities and making use of community champions. 40 While universal and targeted educational interventions are necessary to enable the public to understand the importance of vaccination and are ethically and politically acceptable, they are not enough to modify behaviour or increase confidence. 41 Full endorsement from regulatory bodies is likely to increase confidence 42 , but efforts to combat misinformation, especially around vaccine safety, may be warranted. The rise in vaccine hesitancy as a result of misinformation about safety coincides with the rise in social media, a growing platform for the anti-vaccination movement. 39, 41 A concerted effort to engage with younger adults both online and through traditional communication channels will be needed if confidence in a vaccine is to be achieved and vaccine uptake is to improve in this group, subject to them being included in future vaccination rollout. 

WHO Coronavirus Disease (COVID-19) Dashboard: World Health Organisation

Herd Immunity: Understanding COVID-19

COVID-19 vaccine deployment: Behaviour, ethics, misinformation and policy strategies. London: The Royal Society & The British Academy

Ten Threats to Global Health in 2019: World Health Organisation

Vaccine hesitancy: Definition, scope and determinants

The public's role in COVID-19 vaccination: Human-centered recommendations to enhance pandemic vaccine awareness, access, and acceptance in the United States

Global attitudes on a covid-19 vaccine. Online

Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom

Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. The Lancet Regional Health -Europe

The Catalyst Project T. Social Patterning and Stability of Intention to Accept a COVID-19 Vaccine in Scotland: Will Those Most at Risk Accept a Vaccine? Vaccines (Basel)

Vaccine Hesitancy in the UK: The Oxford Coronavirus Explanations, Attitudes, and Narratives Survey (OCEANS) II

Ethnic disparities in hospitalisation for COVID-19 in England: The role of socioeconomic factors, mental health, and inflammatory and pro-inflammatory factors in a community-based cohort study

Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank

Factors associated with COVID-19-related death using OpenSAFELY

The COVID-19 pandemic and health inequalities

Inequalities in influenza vaccine uptake among people aged over 74 years in Britain

Lower vaccine uptake amongst older individuals living alone: A systematic review and meta-analysis of social determinants of vaccine uptake

Colchester: University of Essex; 2020. 20. Institute for Social and Economic Research

R: A language and environment for statistical computing

Package 'survey' -Analysis of Complex Survey Samples: CRAN

Colchester: ISER University of Essex; 2021. 26. Joint Committee on Vaccination and Immunisation. Advice on priority groups for COVID-19 vaccination: UK Government

Factors associated with uptake of vaccination against pandemic influenza: a systematic review

Predictors of influenza vaccine uptake during the 2009/10 influenza A H1N1v ('swine flu') pandemic: Results from five national surveys in the United Kingdom

The unequal impact of the COVID-19 crisis on minority ethnic groups: A framework for understanding and addressing inequalities

A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation. The Lancet Infectious diseases

Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic

Vaccine hesitancy among Maltese healthcare workers toward influenza and novel COVID-19 vaccination

Vaccine hesitancy: the next challenge in the fight against COVID-19

The French public's attitudes to a future COVID-19 vaccine: The politicization of a public health issue

Vaccination during the COVID-19 Pandemic in China

International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples

Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy

Factors associated with the uptake of seasonal influenza vaccination in adults: a systematic review

Finding a way to address a wicked problem: vaccines, vaccination, and a shared understanding

Improving health and well-being through community health champions: a thematic evaluation of a programme in Yorkshire and Humber

Restoring confidence in vaccines in the COVID-19 era. Expert Review of Vaccines

Factors Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination

4%) 65-74 1532 (15.3%) 75+ 882 (8.8%) Ethnicity White British or Irish 8713 (87.3%) British -Pakistani/Bangladeshi 198 (2.0%) Asian or Asian British -any other group 106 (1.1%) Black or Black British 190 (1.9%) Other Ethnic Group 59 (0.6%) Missing 102 (1.0%) Born in UK Born in UK 8991 (90.1%) Other Degree 4086 (40.9%) A Level or equivalent 2202 (22.1%) GCSE or equivalent

Predictors of COVID-19 vaccine hesitancy